FR3051673B1 - Inhibiteurs de la voie de l'interleukine 17 pour le traitement des infections chroniques dues a hpv - Google Patents

Inhibiteurs de la voie de l'interleukine 17 pour le traitement des infections chroniques dues a hpv Download PDF

Info

Publication number
FR3051673B1
FR3051673B1 FR1654637A FR1654637A FR3051673B1 FR 3051673 B1 FR3051673 B1 FR 3051673B1 FR 1654637 A FR1654637 A FR 1654637A FR 1654637 A FR1654637 A FR 1654637A FR 3051673 B1 FR3051673 B1 FR 3051673B1
Authority
FR
France
Prior art keywords
hpv
interleukin
pathway
inhibitors
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1654637A
Other languages
English (en)
Other versions
FR3051673A1 (fr
Inventor
Vincent Descamps
Florence Brunet-Possenti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Assistance Publique Hopitaux de Paris APHP
Universite Paris Cite
Original Assignee
Assistance Publique Hopitaux de Paris APHP
Universite Paris Diderot Paris 7
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assistance Publique Hopitaux de Paris APHP, Universite Paris Diderot Paris 7 filed Critical Assistance Publique Hopitaux de Paris APHP
Priority to FR1654637A priority Critical patent/FR3051673B1/fr
Priority to PCT/EP2017/062651 priority patent/WO2017202978A1/fr
Priority to CA3025066A priority patent/CA3025066C/fr
Priority to EP17724595.8A priority patent/EP3464353A1/fr
Priority to US16/303,824 priority patent/US11401326B2/en
Publication of FR3051673A1 publication Critical patent/FR3051673A1/fr
Application granted granted Critical
Publication of FR3051673B1 publication Critical patent/FR3051673B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR1654637A 2016-05-24 2016-05-24 Inhibiteurs de la voie de l'interleukine 17 pour le traitement des infections chroniques dues a hpv Active FR3051673B1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
FR1654637A FR3051673B1 (fr) 2016-05-24 2016-05-24 Inhibiteurs de la voie de l'interleukine 17 pour le traitement des infections chroniques dues a hpv
PCT/EP2017/062651 WO2017202978A1 (fr) 2016-05-24 2017-05-24 Inhibiteurs de la voie de l'interleukine 17 pour le traitement des infections chroniques dues a hpv
CA3025066A CA3025066C (fr) 2016-05-24 2017-05-24 Inhibiteurs de la voie de l'interleukine 17 pour le traitement des infections chroniques dues a hpv
EP17724595.8A EP3464353A1 (fr) 2016-05-24 2017-05-24 Inhibiteurs de la voie de l'interleukine 17 pour le traitement des infections chroniques dues a hpv
US16/303,824 US11401326B2 (en) 2016-05-24 2017-05-24 Method of treatment of human papillomaviruses related chronic infections

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1654637A FR3051673B1 (fr) 2016-05-24 2016-05-24 Inhibiteurs de la voie de l'interleukine 17 pour le traitement des infections chroniques dues a hpv
FR1654637 2016-05-24

Publications (2)

Publication Number Publication Date
FR3051673A1 FR3051673A1 (fr) 2017-12-01
FR3051673B1 true FR3051673B1 (fr) 2018-06-22

Family

ID=57136975

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1654637A Active FR3051673B1 (fr) 2016-05-24 2016-05-24 Inhibiteurs de la voie de l'interleukine 17 pour le traitement des infections chroniques dues a hpv

Country Status (4)

Country Link
US (1) US11401326B2 (fr)
EP (1) EP3464353A1 (fr)
FR (1) FR3051673B1 (fr)
WO (1) WO2017202978A1 (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
KR20130100346A (ko) * 2010-11-04 2013-09-10 442 벤쳐스 엘엘씨 피부 상태를 치료하기 위한 조성물 및 방법

Also Published As

Publication number Publication date
US11401326B2 (en) 2022-08-02
FR3051673A1 (fr) 2017-12-01
US20200308269A1 (en) 2020-10-01
WO2017202978A1 (fr) 2017-11-30
EP3464353A1 (fr) 2019-04-10
CA3025066A1 (fr) 2017-11-30

Similar Documents

Publication Publication Date Title
MA45539A (fr) Dihydropyranopyrimidines pour le traitement d'infections virales
EP3340982A4 (fr) Composés pour le traitement de troubles immunitaires et inflammatoires
MA44083A (fr) Composés de biarylmonobactame pour le traitement d'infections bactériennes
EP3570844A4 (fr) Azolopyrimidine pour le traitement de troubles liés au cancer
EP3490987A4 (fr) Nouveaux agents thérapeutiques pour le traitement de l'infection par hbv.
MA47719A (fr) Esketamine pour le traitement de la dépression
FR3046933B1 (fr) Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
MA54925A (fr) Compositions pour le traitement de troubles acido-basiques
MA51418A (fr) Inhibiteurs de glycolate oxydase pour le traitement de maladies
MA44737A (fr) Compositions pour le traitement de troubles liés à l'hyperkératose
MA56412A (fr) Thérapie par l'arn messager pour le traitement des maladies articulaires
EP3766497A4 (fr) Médicament pour le traitement de la toux
MA42999A (fr) Polythérapie pour le traitement de malignités
EP3291693A4 (fr) Régime alimentaire imitant et favorisant le jeûne pour le traitement de l'hypertension et des troubles lipidiques
EP3344325A4 (fr) Administration locale de médicaments pour le traitement de l'asthme
EP3430400A4 (fr) Schémas posologiques pour le traitement d'infections fongiques
EP3740246C0 (fr) Perturbation du complexe linc pour le traitement de laminopathies
EP3866777A4 (fr) Polythérapie pour le traitement de maladies inflammatoires
MA55218A (fr) Eskétamine pour le traitement de la dépression
EP3716966A4 (fr) Compositions d'alpha-cétoacides pour le traitement de l'hypoalbuminémie
EP3316887A4 (fr) Inhibiteurs de gls1 pour le traitement de maladies
MA39927A (fr) Inhibiteurs de glyt1 pour le traitement de troubles hématologiques
EP3612214A4 (fr) Optimisation d'enzymothérapie de remplacement pour le traitement de l'homocystinurie
EP3541379A4 (fr) Compositions pour le traitement de l'hypertension
MA42985A (fr) Traitement de troubles liés à l'acide biliaire

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20171201

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8

CD Change of name or company name

Owner name: UNIVERSITE PARIS CITE, FR

Effective date: 20230621

Owner name: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, FR

Effective date: 20230621

TQ Partial transmission of property

Owner name: UNIVERSITE PARIS CITE, FR

Effective date: 20230621

Owner name: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, FR

Effective date: 20230621

PLFP Fee payment

Year of fee payment: 9